

# Edwards Lifesciences

## TCT 2022 Investor Update

September 17, 2022



Edwards

# Cautionary Statement

Presentations and comments made today by management of Edwards Lifesciences Corporation (the “Company”) will include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can sometimes be identified by the use of words, such as “may,” “will,” “should,” “anticipate,” “believe,” “plan,” “project,” “estimate,” “potential,” “predict,” “unstoppable,” “early clinician feedback,” “expect,” “intend,” “guidance,” “outlook,” “optimistic,” “aspire,” “confident” or other forms of these words or similar expressions and include, but are not limited to, the Company’s financial goals or expectations for 2021, 2022 and beyond (including sales, underlying growth, foreign exchange impact on sales, gross profit, earnings per share and its key components, free cash flow, SG&A, R&D, tax rate, operating margin, diluted shares outstanding, and other financial expectations); expectations for our products (including headwinds and tailwinds, growth drivers, expected global opportunity, the timing and results of clinical trials, regulatory approvals, and reimbursement coverage); industry growth projections; the Company’s rate of penetration in individual and global markets; forecasted trends in patient treatment and demographics; strategies for the Company’s new and existing products; and continued development of future innovations.

Statements of past performance, efforts, or results about which inferences, or assumptions may be made can also be forward-looking statements and are not indicative of future performance or results. Forward-looking statements are based on estimates and assumptions made by management of the Company and are believed to be reasonable, though they are inherently uncertain, difficult to predict, and may be outside of the Company’s control. The Company’s forward-looking statements speak only as of the date on which they are made, and the Company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of the statement. If the Company does update or correct one or more of these statements, investors and others should not conclude that the Company will make additional updates or corrections.

Forward-looking statements involve risks and uncertainties that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements. Factors that could cause actual results to differ from that expressed or implied by the forward-looking statements are detailed in the Company’s periodic reports filed with the U.S. Securities and Exchange Commission.

# TCT 2022 Investor Update Agenda



## Opening Remarks

Mike Mussallem

## CLASP IID Synopsis and PASCAL Experience

Ted Feldman, MD and Scott Lim, MD

## TMTT Q&A

## SAPIEN 3 Ultra RESILIA and SAPIEN X4

Larry Wood and David Wood, MD

## TAVR Q&A

## Closing Remarks

Mike Mussallem

# CLASP IID Synopsis and PASCAL Experience



**Bernard Zovighian**

Corporate Vice President  
Transcatheter Mitral and Tricuspid  
Therapies



**Ted Feldman, MD**

SVP, Medical Affairs  
Transcatheter Mitral and  
Tricuspid Therapies



**Scott Lim, MD**

Professor of Medicine & Pediatrics  
at the University of Virginia and  
Medical Director of the UVA  
Advanced Cardiac Valve Center

# TMTT Q&A



Edwards

# SAPIEN 3 Ultra RESILIA and SAPIEN X4



**Larry Wood**

Corporate Vice President  
Transcatheter Aortic Valve  
Replacement



**David Wood, MD**

Director, UBC Centre of Cardiovascular Innovation  
Head, Division of Cardiology, Vancouver  
Professor of Medicine, University of British Columbia

# TAVR Q&A



Edwards



Edwards